Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Boehringer Ingelheim
Farmers Insurance
Medtronic
McKinsey
Colorcon
Cerilliant
Argus Health
Moodys

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,125,560

« Back to Dashboard

Which drugs does patent 7,125,560 protect, and when does it expire?


Patent 7,125,560 protects TOPAMAX and TOPAMAX SPRINKLE and is included in one NDA. There have been zero Paragraph IV challenges on Topamax and Topamax Sprinkle

Protection for TOPAMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in thirty-one countries.

Summary for Patent: 7,125,560

Title:Pharmaceutical composition of topiramate
Abstract:The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.
Inventor(s): Thakur; Madhav S. (North Wales, PA), Kotwal; Pramod M. (Blue Bell, PA), Gibbs; Irwin S. (Huntington Valley, PA)
Assignee: Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)
Application Number:10/748,764
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Pharms
TOPAMAX
topiramate
CAPSULE;ORAL020844-001Oct 26, 1998ABRXYesNo► Subscribe► SubscribeY
Janssen Pharms
TOPAMAX
topiramate
CAPSULE;ORAL020844-002Oct 26, 1998ABRXYesYes► Subscribe► SubscribeY
Janssen Pharms
TOPAMAX SPRINKLE
topiramate
CAPSULE;ORAL020844-003Oct 26, 1998DISCNNoNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,125,560

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,696,091 Pharmaceutical composition of topiramate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,125,560

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland343894► Subscribe
Poland194559► Subscribe
New Zealand506532► Subscribe
Norway20004311► Subscribe
Malaysia125821► Subscribe
Japan2003530295► Subscribe
Israel138032► Subscribe
Indonesia26982► Subscribe
Hungary0301192► Subscribe
CroatiaP20000563► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Cipla
Deloitte
Cantor Fitzgerald
Harvard Business School
Moodys
Healthtrust
QuintilesIMS
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot